Why the study?
MINOCA carries a non-negligible risk of mortality and morbidity, but prospective clinical trials are lacking and treatments for obstructive MI cannot be assumed to translate.
Highlights the need for multimodality imaging and personalized therapeutic approaches in patients with MINOCA, given its non-negligible risk of adverse outcomes.
Answers are grounded in this paper and cite their sources.
MINOCA carries notable long-term risks; leaves open evidence-based management pending dedicated prospective trials.
Myocardial infarction with non-obstructive coronary artery (MINOCA) disease represents a heterogeneous clinical conundrum accounting for about 6% of all acute myocardial infarction (MI) cases. Initially believed to be a benign condition, is now becoming clear that MINOCA is associated with a non-negligible risk of mortality, rehospitalization, disability and angina burden at follow-up, with high socioeconomic costs. To date, there are no prospective clinical trials in this population and cannot be assumed that benefits observed in patients suffering from MI with obstructive coronary artery disease may successfully translate to this syndrome. Herein, we comment on the importance of the multimodality assessment to properly identify and treat the specific causes of MINOCA, in order to improve prognosis and the quality of life in these patients.
No takes yet. Share an insight, caveat, or question.
Buono et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: